Tagged with GE

Spain STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In addition, she analyses the biosimilars market in Spain, where the company recently launched Bevacizumab, and comments on the importance of…

Global Recent reportage from Global Data Research and Clinical Trials Arena has ranked the world’s leading biopharma companies best positioned to take advantage of future biosimilars disruption. The ranking considers the number of jobs listed by each company mentioning biosimilars, deals conducted, and company filing mentions in the period between January…

Italy Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in the early studies of remdesivir as a treatment against severe COVID-19 disease; how Gilead is working to eliminate viral Hepatitis…

Global As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development process to better understand their needs. However, as the below insights from four of Novartis Oncology’s patient engagement leads show, successfully integrating patient…

MEA Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma executives overseeing his region need to succeed.   As region head for a company that is only 40 years old,…

Global One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems so great, but the evidence remains so patchy.   So far, top tier regulators such as the US FDA and…

Australia Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how artificial intelligence (AI) solutions can best be applied to pharmacovigilance in Australia, and the challenges that stand ahead.   For…

Global Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as a revolutionary, perhaps even decisive, new pillar in the war on cancer. Five years later, however, many are still left…

MEA The top 10 fastest growing pharma companies in the Middle East and Africa (region) ranked by previous period growth between MAT Q2 2020 and MAT Q2 2021. The list is dominated by regional players including Julphar, Sedico/Acdima and Eva Pharma, but multinational firms are also represented by Gilead Sciences, Takeda,…

China Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s reimbursement list in 2021; the former GSK scientist pleading guilty to stealing trade secrets for Chinese pharma; and BioNTech’s continuing…

Global In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand along the life science continuum, providing positive healthcare…

Italy The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of Menarini’s Europe commercialisation deal for Karyopharm’s NEXPOVIO in Europe.   Angelini Pharma Appoints Rafal Kaminski as New Chief Scientific Officer…